Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Pharma Sessions

Pharma Sessions artwork

Speed is the Need: Launch strategy with Hetal Patel

Sep 11, 202527 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this episode of Pharma Sessions, host Jonathan Kaskey talks with Hetal Patel, VP of Medical Affairs at Celltrion USA, about building a medical affairs function from the ground up while launching multiple drugs. Sounds like a hot pot of pressure, decision-making and sleepless nights, doesn't it? Well, don’t let this intimidate you just yet. From transitioning out of big pharma to scaling systems with limited resources, Hetal shares practical strategies for thriving in high-pressure launch environments and how to do so without burning out. Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_00Me, when I walked in here, I did not even have a job description. I can create my own blueprint from scratch.

SPEAKER_01Hello, hello, and welcome to Pharma Sessions, a place for pharmaceutical leaders to come and learn from each other. I'm your host, Jonathan Kaskey. Technology and market trends are bringing change at an ever-accelerating rate, and no person, team, or company can afford to be left behind. Here, we dive into the strategies and tactics that our guests use to tackle these challenges and create new opportunities and how you can do the same in your own organization.

SPEAKER_01What have you had to eat so far today?

SPEAKER_00Just two cups of coffee. I'm not a much morning eater or a breakfast person, so my day usually starts six o'clock, seven o'clock in the morning. So I'm not much of a morning eating person, but I'm sure after this episode I'll get something to eat.

SPEAKER_01Okay, very good. Well, at least you're fully caffeinated and ready to go.

SPEAKER_00Much needed. How about you?

SPEAKER_01I found the most wonderful overnight oats recipe. It's like it's healthy, it's made with almond milk and spices and chopped up dates. And it's like a nice slice breakfast. I have it with a coffee and it gets me, it gets me through a large chunk of the day.

SPEAKER_00That's awesome. Maybe after this episode, I'll ask you for the recipe.

SPEAKER_01Absolutely. I'll I'll put it in the show notes. A couple episodes ago, I put a pancake recipe in there, and people seem to like that. So I'll give you uh nice. I'm a big breakfast person. All right. So let's jump right in. So you're currently with Celtryon USA. What is your current role there and kind of what brought you to them?

SPEAKER_00Sure. So my cutting role is I'm the vice president of medical affairs at Celtryon USA. And I can walk you through the journey as to how I got here. A little bit about myself. I am a pharmacist by education and also have an MBA. My earlier careers started as a clinician, which really grounded me in patient-centered care. So I did work as a clinical pharmacist at one of the hospitals in Chicago for almost eight years. And from there I transitioned into working as an investigational drug pharmacist, overseeing various clinical trials across multiple therapeutic areas.

SPEAKER_00It gave me an understanding into the multifaceted approach of a drug approval. The next transition after that was easily to get into medical affairs. I have spent most of my career now in the pharma industry, and I worked across multiple companies such as Janssen through Cineos, Coheris Biosciences, Greenwich Biosciences, which is now part of Jazz Pharma. And over there, most of my work had been doing either evidence generation, working cross-functionally with medical, commercial, global, regulatory affairs, launching multiple products, and then building field teams.

SPEAKER_00So when this opportunity came to work at Saltryon USA almost two years ago, what really excited me about this is to build something from scratch. I didn't only want to manage what's there, but to build it from ground up. So that's where the journey started here for me two years ago in 2023. It's actually just yesterday was two years since I've been to Celtryon USA.

SPEAKER_01Congratulations. So the working title we have for this episode is Ready Set Launch. And I think when we were doing the prep calls, you were describing starting at Celtryon USA almost immediately before a launch. So when you say the opportunity presented itself, what was the opportunity and what was appealing about it?

SPEAKER_00Absolutely. So as I mentioned, I do like something to build from ground up to something really create something. Now Celtryon USA is part of Celtrion. Celtrion is a global company. Our headquarters is in South Korea, but we do have offices in close to 35 countries. Celtrion is really steeped in deep scientific roots. It has global outreach. But back in 22-23, they were really looking to build their whole Celtryon USA operations here in the US.

SPEAKER_00So it was really in the really early innings back then. So for me to come at that time and build a whole function of medical affairs at Celtryon USA while launching multiple drugs. When I first came on board in May, we were getting ready to launch one drug in three weeks. Second drug was going to be launched in three months. And then we were also gearing up for a strong pipeline and rich pipeline that we had. Fast forward now to two years, we have four drugs approved and launched in the markets.

SPEAKER_00Remaining four drugs that are approved and waiting to be launched in the US market. So this was a mix of challenge and opportunity, right? So you needed to have an agility of a startup, but to also function at the scale of a global player. So I took that as an opportunity to come here and build something. That was something that I found really exciting.

SPEAKER_01And where were you immediately before? I know you should could have shared the brief background, but you were at Greenwich that had been acquired, or where were you right before Celtryon USA?

SPEAKER_00Before Celtryon, I was at Coheris Biosciences. I was there for three years in the medical affairs uh team and where I worked as a medical science liaison as well as a player coach. And primary of a focus at Coheris Biosciences was biosimilars. And when I came over to Celtrion, they were also looking for somebody with an expertise in biosimilars and the US market. So then it was a natural transition.

SPEAKER_01Gotcha. So when you started three weeks before launch, which is kind of crazy, right? I believe you were in a senior MSL or MSL director role. How was the work you were doing in that environment different from what you might have been doing at a large company in the same role? And I kind of asked that because there are a lot of people that listen to this that are big companies, small companies, and there's always this feeling of is the grass greener on my side or the other side? So what are some of the differences?

SPEAKER_00That's a great question, Jonathan. So people coming from big companies, they know what is expected of them. They have all the groundwork laid down, they have all the foundations laid down. Me, when I walked in here, I did not even have a job description. But I can find me. I found it personally, due to my personality, the way I was looking at it, I found that I can create my own blueprint from scratch. In many essence, it was quite challenging, but quite interesting as well, because there was no job description.

SPEAKER_00And be it as an MSO or an MSL director or wherever you're part of a startup, you do essentially everything. You're wearing multiple hats, you're doing multiple things at the moment. So I remember in those early stages, I was manually writing the SOPs. I was building the hiring and onboarding and training programs for the MSLs. I was interviewing MSLs. I was creating resources for field work, right? Those uh presentations that MSLs will be utilizing in the field.

SPEAKER_00I was working with the payer team for getting access informal. I was working with commercial training programs. So multiple different things that was being done at that time. But it was incredibly fast-paced, but it was also incredibly satisfying. And not every day do you get a chance to leave your legacy behind where you're building something from ground up and being part of something that's amazing, where you can now say two years you've launched multiple drugs in such a short period of time.

SPEAKER_01Right. That is really a huge accomplishment. So how do you I mean, how do you manage all that, right? Because a lot of what you described, any one of those activities, if you're working at a Pfizer or BMS, that could be a single person's whole job. And you still have to do all the other stuff. So how do you actually manage doing all of that?

SPEAKER_00Back then, we knew that the speed was the need. We had to operate extremely efficiently, but we had to scale quite quickly. So at that time, trying to juggle multiple things while making sure things are done or are built in a compliant manner was quite challenging. And on top of that, if you add a layer of aligning the global US web functions with the US functions was also different where you're working with a global company and trying to adapt their ways to a US medical function, our ways also.

SPEAKER_00So that was also quite challenging. But what I what held me going first was in a startup company, it is a caliber of people that you work with. You have the opportunity and the flexibility to tap into the talent of pool that's across various departments, and which probably you may not find in a big company that uh they are often siloed with each other. So here we rely so much on each other. Collaboration is not optional, collaboration is critical over here. You have to be working together.

SPEAKER_00For me, it again was triaging. What needs to be done today, what can be done tomorrow, and what can be first done later, right? So for me, that was again helped me navigate through priorities, uh, what was needed and was also important that all the time we needed to know that why are we doing and what are we doing? What brought me to Saltrion was the promise of all the drugs that we are bringing, the valuable affordable medications for patients, patient improving patient access, the people and the pipeline.

SPEAKER_00It was challenging, but yes, we did get through one step at a time, building one block at a time, and now we are here. Back then, I used to call it as building the plane as I fly. Even now, as I'm building my team and I'm interviewing MSLs for building my team, I tell people I'm still building my plane as I fly. I'm still about the Atlantic Ocean, but I'm still building it. That was needed back then, you know, putting the foundation. But now I am looking for more efficiency, right? So one thing at a time, one step at a time.

SPEAKER_01So a couple of things you said that I think are just very, very cool. So the speed was the need. I remember at one point I was interviewing and I was going from the biggest company I'd ever worked for. I've always been on the tech side to a startup, like a 25-person startup. And at the time at the big company, I was in the midst of this protracted, like year-long MSA master services agreement negotiation with a big pharma company where there was over a million dollars of business kind of just sitting there if we could get our lawyers to agree to certain things. And it was just take we just couldn't.

SPEAKER_01And I ended up as I was interviewing, I was talking with the CEO of this company. He's like, Oh, I have to take a call. Why don't you sit in? Because it'll give you a sense of how we work. And it was an MSA negotiation, and he was literally making decisions, right? And he's like, Oh, we can do this, we can't do this, right? But it was being done in what was taking me a year and probably in a half an hour to an hour. And it was a very different mindset. Not that there weren't good reasons for why they were saying no to certain things, but the speed was the need, I think, is very, very important when it's a smaller company.

SPEAKER_01And the other thing that you said that I like quite a lot is this idea of triaging. So even in my day-to-day, I'd grab this. This is to-do list, right? So I always, every day I have a list and it fits on a note card. And if it gets longer than the note card, then something else has to get crossed off the note card because you can only do so much. So really, you have to work only on the most important things and then figure out how you can rely on other people or systems or or whatever to do anything else, or else you just go crazy. Absolutely. The answer is not to work 12 hours a day, right?

SPEAKER_01That's not the answer. The answer is to figure out how to do a really good job in a reasonable period of time. So you don't, you know, keel over at your desk. Yes. Work hard and work smart. Exactly. Building the plane, so you still feel you've a couple years in, four drug launches behind you, for coming, you're still building the plane. That still is your mindset, or how has that shifted? Great, because you have to have some of that stuff done at this point.

SPEAKER_00Yes. So I feel like I have the majority of the plane built. I'm probably just adding the wings to it, if you may. Right now I'm expanding the team to 14 MSLs. So I'm interviewing, hiring people, getting more on place because of the multiple drug launches and approvals that are set for the pipeline. And I'm also right now in the refining stage. Right back then, you know, I was not waiting for direction. I created the direction. We did it what was needed at that time, and we'll refine it later. So now I am expanding and refining the processes that we've laid in place, you know, so we can efficiently work through multiple products.

SPEAKER_00Yes, back then it was two products in three months. We managed to do it, and we did it in a smart way, we did it in an efficient way, we built the systems, we empowered people. But now we want to take it to the next stage to make it more sustainable that all those multiple drugs coming, you know, can be supported by the medical affairs function. Because honestly, I feel medical affairs has come such a long way from what it was before. Earlier, it was just being the scientific backbone or providing medical information or scientific data.

SPEAKER_00But now it's so much more, it's into strategy. It's in a cross cross-collaboration with regulatory, with commercial, with marketing, creating your messaging. So I do feel that having a strong medical affairs for the team for a company plays an essential role in the pre-launch, peri-launch, and post-launch phase of a drug.

SPEAKER_01All right. Let's help you solve this problem. So, how many, how many MSLs do you have? And you said you're going for 14. How many do you currently have?

SPEAKER_00I do. So I have seven MSLs. I have seven MSLs. I just hired four MSLs. Well, one, the offer is extended. I'm looking for three more. And I'm also looking to hire one regional team director. I have one and I'm looking to hire one more regional team director. So, anyone listening, if they want to apply, please let me know.

SPEAKER_01No, I think this is so let's talk about this because honestly, one, that would be a really cool outcome. But also, I think it has to be different when you're hiring MSLs at a company like the environment you just described. When you're trying to build a team and make sure everybody is meshing and working well and collaborative as you were just describing, what are you looking for? What are kind of the key things where it's like, oh, yeah, this person could really bring something of value and it's worth exploring?

SPEAKER_00Absolutely. So, first and foremost, as I mentioned, in a startup culture or the place that Saltry and USA is right now, collaboration is so critical. I rely heavily on my current team. You know, I want to us all to write the playbook together of Salt Trian US Medical Affairs. So each brings in their unique sets of strengths and weaknesses and personalities, and we all work together to now refine the system that we've created. So when I'm interviewing the MSLs, as much as I love to coach and mentor and help new aspiring MSLs at this stage where Saltrian USA is with multiple launches coming up, I feel I need some MSL experience.

SPEAKER_00But also apart from that, what I'm looking in a person is are they solution-oriented? Are they self-starters? Are they adaptable?

SPEAKER_01So, how do you interview for that? Because that's it's something that I've struggled with, right? Because he's, well, are you solution-oriented? And everybody says, yeah.

SPEAKER_00It sometimes gets tricky. And again, I rely highly, heavily on my other commercial counterparts to also interview and see if they've able be a fit for this team. But I do ask them questions as to if you have certain kind of roadblocks or you don't have this process in place. How do you navigate through that? Right. And that gives me an insight into their personality. Are they solutions oriented? You know, are they self-starters? Do you are they looking for solutions or they just come up with, oh, this is not working? Right. So for the need, that is extremely important. And I want them to hit the ground running, which is what is probably required over here in my MSL position.

SPEAKER_00So those are some of the things I do look for MSLs coming here. And again, if person coming maybe probably from a big company, they may be expecting upset processes and rigidity. Perhaps they may not be a fit for Sultry and USA right now. I'm not saying that they are less capable or less experienced. It may just not be the right fit at this time if they're looking for set processes. So these are small, small things. I'm looking in a person. And for me, at this point, teen team culture is so extremely important. The team that I have right now, they are amazing.

SPEAKER_00They understand what's required, what's there, what's not there, and what needs to be done. And we all pitch into help. So that is something that I extremely value when I'm interviewing a person.

SPEAKER_01I mean, a lot of what we talked about today is the difference between big pharma and startup world. But I can share from my own experience when I was managing a sales team at a true startup. It was like 12 people on the MIT campus and across two rooms. And we needed to hire some salespeople. I was living in Boston. HubSpot at the time was just blowing up, and they've continued to. Now they're a huge public company. But it's like they give really good training. I'm just gonna hire whoever I can. I'm gonna poach from HubSpot, basically. And so I got some people that we were super excited to have over, and it just didn't work because they were used to this system of everybody knows who you are.

SPEAKER_01They sort of know you're getting spoon-fed all of this stuff. And that wasn't the case at my company. And as much as you try to think about that and describe it, it's a big difference. I've kind of shifted. And now the questions that I like to ask to kind of get at that is about describing a challenge you've faced and how you've overcome it, or describe a time that you've come up with an innovative approach. And then you can talk two, three levels deep on that because no matter what the job, there are always creative ways to try to solve problems.

SPEAKER_01And I think more than anything, for me personally, what I'm looking for in startup environments is that mindset of this is what we're faced with. Now, how are we going to solve it? And I think that's a lot of what you were describing at the very beginning about doing all of the medical queries, the clinical presentations, the ad boards, the conferences, the payer presentations. One way is to look at that as, oh my God, that's overwhelming. Another way is, well, here's the challenge. I only have so many resources and I have all the stuff I need to do.

SPEAKER_01So how are we going to marry those two things?

SPEAKER_00That's a great question. So, yes, back in those days, it was quite challenging. That time, the goal was to build what we need and build something that's scalable. And that time, doing multiple things at one time is I knew that I was sitting on such vast, rich knowledge of insights. I've been talking to payers, I've been attending conferences, I've been meeting these HCPs, I've been meeting these leaders and influencers, and they're telling us so many great things about our drug or a product or the landscape or all of that, right?

SPEAKER_00And they were there, they were siloed, like, okay, we went to this one meeting, it's there. We went to this meeting with how do I create that into an action? How do I take it next step? So it was sitting there, nothing was done. But I think now that I have my team and now that we have everybody, we have actually created an insight team. You know, we call it an IT for lack of creativity, but we call them an IT team, and it's really great. We are working now to look at literature, to look at social media listening, look at conferences, look at what the individual MSLs when they meet with the HCPs are doing and gather all of those insights and analyze them, digest them, and tell us that will give us a strategy.

SPEAKER_00Okay, now that a drug is in the market for a year or two years, what is the next step I need to take? Where should I pivot? Where should I focus my strategy or field tactics in? So that is something I felt that has been that was a challenge two years ago. I didn't have the time or the bandwidth to do that, right? Because you're about multiple hats. But now that I have, I can take a step back and look at the big picture. So we can zoom out, if you may, and then figure out my strategy. So I think that has been something that I feel that has helped me develop something.

SPEAKER_01That's very interesting. I mean, everything you're describing is very cool, right? It's now you have a little bit of breathing room and you're using that to take a step back and be strategic about I won't say that, that I have breathing room, but yes, I can breathe. That's good. If you've been enjoying the conversations here on Pharma Sessions, you should know they're made possible by the team at Xunt. XSunt helps life sciences companies turn complex data into clear, actionable insight. For years, XSunt has made complicated data sets simple to help commercial, medical, and operations teams map what's happening, predict what's next, and make stronger decisions faster.

SPEAKER_01And now there's an added AI layer that makes everything work so much better. I was actually pretty jaded about some of the AI approaches I had seen, but when XSunt showed me theirs, I actually left my job to come work for them. It's really awesome. So if you want to understand your market, your customers, or your performance with more clarity than ever, check out xunt.com. That's xsunt.com. All right, let's jump back into the episode. Well, if I was an MSL, I'd be applying. So I think you've developed something really interesting.

SPEAKER_01And so these next four drugs that you're going to launch, there must be some learnings. Like, what do you think you'll be doing differently for the next ones than you've you did for the previous ones?

SPEAKER_00Start ahead of time.

SPEAKER_01Typically not three weeks in advance.

SPEAKER_00Not three months for sure. Absolutely. But I think yes, usually typically a medical affairs team comes into being if it is a new, brand new biologic drug or brand new drug, at least 24 to 36 months before the drug is getting applied. For biosimilars, it may be slightly different. Nevertheless, a medical affairs team comes into being at least 12 months before a drug is approved by the FDA. So those are the lessons that I learned in the past. So hoping with upcoming drugs, approvals, and launches, I'm much more prepared. I have all the resources developed.

SPEAKER_00My team is trained to answer the queries, medical information system is in place. So it's much more defined and the foundation is in place. So I feel that it's I'm much more prepared going on for these different launches.

SPEAKER_01Nice. So as we wrap up here, if you had any words of wisdom from going through this experience over the last really just a couple of years, you said 2023, right? Yeah. Put yourself in the position of yourself right before you made that decision. What are your words of wisdom for somebody who's going in, starting, writing their own job description and building Metafairs from scratch?

SPEAKER_00I feel that I would like to say don't be afraid to take the risk. If you're going walking into a blank slate, some may feel challenged or scared that, oh, what is the next day going to hold? What's the next week going to hold? What's the next month going to hold? You don't know. But that also gives you an opportunity to expand yourself, to grow, to learn and to establish something. You know, I think we proved that medical affairs is important. We can build something fast and we can build something smart as long as we have the right mindset and the right set of people with you.

SPEAKER_00So I'm really excited to see where medical affairs goes in the future to be nimble, deeply rooted in patient care, but at the same time to be adaptable and take what the challenge comes for you. And something that I would also like to add is, you know, we've talked a couple of times about the startup culture or in small pharma versus a big farmer. It's not everybody's made for everybody. So some people may be welcoming with the startup culture. Some people only like these trends and all that.

SPEAKER_00I've worked with Jansen, I worked with Greenwich Biosciences, Jazz Pharma, and now in a small company. So I've kind of seen both sides. Both sides have its pros and cons on a very personal light note. I like it over here because my name is Patel. But as you know, Patel is such a common name. At least here, there is no number after my patel. I'm the first patel in the company, right? So that's you know, when I was a Jansen or any other, I was something Hagel Patel 700 or 800 or something.

SPEAKER_01H. Patel 35, yeah, exactly. That's fantastic. So yeah, and I think what you said about earlier about leaving a legacy, right? You can look back and say, you've made a huge impact on this company, on ultimately it's about getting the drugs into patients' bodies. And if you don't have a successful lunch, the drugs don't get out there and people don't get the medicine, right? So that is a tremendous accomplishment.

SPEAKER_00Absolutely. And when I talk to patients or patient advocacy groups and the impact that these biosimilars or even our other drugs, novel biologics, have made, it's deeply satisfying to see. Yes, we hustled for the last two years, we got things running. But when you talk to these patients and we see the difference that makes, that is something that makes every day worth it.

SPEAKER_01Excellent. Well, let's leave it there and thank you so much for joining. This was a lot of fun. And that's a wrap on today's episode of Pharma Sessions with me, Jonathan Kaske. If you enjoyed today's conversation, don't forget to hit follow or subscribe and share it with someone else in the pharma world who might need to hear it. For more on pharma trends, career growth, and business strategies, connect with me, Jonathan Kaske, on LinkedIn.

SPEAKER_01Until next time, thanks for listening.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Built to Move: Candel Therapeutics' Agile Path from Trial Results to Launch Readiness

    Nov 4, 202636 minAudio

    Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...

    Credit the people on this episode

  2. Data, AI, and the Future of Field Training with Annel Duckels from BMS

    Sep 24, 202617 minAudio

    In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...

    Credit the people on this episode

  3. Hallway Interviews with Pharma Learning Leaders

    Jul 31, 202639 minAudio

    Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...

    Credit the people on this episode

  4. Blockchain + AI: The Future of Healthcare Data

    Jul 9, 202633 minAudio

    What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...

    Credit the people on this episode

  5. The Question Behind the Question - Field Training with Jennifer Muszik

    Jun 8, 202629 minAudio

    What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...

    Credit the people on this episode